Advertisements

Метионин

Quick links to important sections

Метионин

Selected form

Advertisements
Advertisements

Method of action: Hepatoprotective

Treatment option: Hepatitis, Toxic Hepatitis, Cirrhosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Метионин

Quick Facts

Property Description
Active ingredient Methionine (INN)
Form Capsules, Tablets, IV Solutions
Pharmacological class Amino Acid Supplement; Hepatoprotective Agent
Common use (General) Supporting protein synthesis and liver function
Origin Essential Amino Acid (Dietary source required)

1. What is Methionine (Метионин)?

Methionine is an essential amino acid and the active substance (INN: Methionine) in supplements and medical products, broadly classified as an Amino Acid Supplement and a Hepatoprotective Agent (liver protector). It is considered "essential" because the body cannot produce it internally and must acquire it entirely through food or supplementation.

This substance plays a central role in human metabolism. Unlike many amino acids the body can synthesize, Methionine's essential status makes it a required nutrient for cell maintenance, protein synthesis, and the production of vital compounds. Its therapeutic value is tied to its distinction as a unique sulfur-containing amino acid, which has been clinically recognized for its essential metabolic and protective functions.


2. What Forms and Types is it Available In?

Methionine is primarily available for consumer use as a single-active ingredient in oral capsules or tablets, intended for the oral route of administration. In the pharmaceutical market, Methionine is available under its INN but is also featured in numerous popular branded supplements, often targeting nutritional support for the liver. In clinical settings, the substance is a mandatory component of combination parenteral solutions (IV solutions) used to provide comprehensive nutrition to patients who cannot eat.

Forms include L-Methionine (the biologically active, natural version) and DL-Methionine (a synthetic mixture). The oral forms typically use simple bases and fillers suitable for ingestion.


3. Why is Methionine Important for the Body?

The general purpose of Methionine is to act as a foundational building block for proteins and to initiate a crucial chemical process known as the methylation cycle, which supports overall cellular health and detoxification. It is often highlighted for its general protective role in liver function and for helping the body manage toxic substances, such as supporting the emergency management of certain types of poisoning, making it a typical neutral use scenario in medicine.

Methionine is critical because its metabolism is the starting point for producing SAMe (S-adenosylmethionine), which is the body’s primary methyl donor, and other essential protective molecules, including the powerful cellular antioxidant Glutathione. This foundational function makes it an integral part of the body's natural defense and metabolic system.

Regulatory References

  1. Methionine: Essential Amino Acid Overview
  2. Amino Acids (MedlinePlus)
Advertisements

What side effects are possible with Метионин?

Possible Side Effects and Safety Information

The safety profile for Methionine is primarily defined by high-level constraints related to its role as a sulfur-containing essential amino acid, with risks concentrating at high intake levels or in the presence of specific pre-existing conditions.

Documented Adverse Reactions

Adverse reactions associated with the use of Methionine are generally dose-dependent, meaning they are more likely to occur with large daily amounts than with standard supplementation.

System-Organ Class Documented Adverse Reactions
Gastrointestinal Disorders Nausea, Vomiting
Nervous System Disorders Headache, Agitation, Confusion (associated with high doses)
Metabolic Disorders Increased blood homocysteine, Altered serum pH (acidosis), Reduced serum folate

Standard frequency categories (e.g., Common, Uncommon, Rare) are typically not published for the single-ingredient supplement form.


Serious Safety Constraints

The most serious safety concerns are directly linked to the body's capacity to process Methionine and are not general adverse effects:

  • Precipitation of Hepatic Encephalopathy: Use is strictly restricted in individuals with severe hepatic impairment or cirrhosis. Methionine metabolism can worsen the condition and lead to this severe neurological complication.
  • Cardiovascular and Acid-Base Status: Due to its metabolic pathway, Methionine use is generally contraindicated in patients with acidosis or conditions such as atherosclerosis where elevated blood homocysteine levels are a significant concern. High-level safety notes indicate that the elevation of homocysteine can be mediated by co-factors like Folic Acid and B vitamins.

These constraints define the regulatory safety framework, emphasizing that the primary risks are tied to pre-existing conditions and dose-dependent toxicity.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Methionine overdose is defined by the risk of excessive metabolic accumulation and resulting severe complications. Overdose management focuses strictly on documented clinical manifestations and regulator-mandated emergency actions.

Documented Overdose Manifestations

Clinical manifestations associated with excessive plasma Methionine concentrations (hypermethioninemia) include specific symptoms of cerebral oedema (brain swelling), such as morning headaches with vomiting and visual changes. The central nervous system (CNS) is the physiological system documented as affected by this accumulation.

Serious Outcomes and Urgent Action

Property Description
Life-Threatening Risk Cerebral oedema is the documented severe, life-threatening outcome associated with hypermethioninemia .
Critical Threshold Plasma concentrations significantly above 1,000 mu mol/L are explicitly documented as the critical level associated with this risk.
Required Action Official regulatory guidance mandates to call a poison center or a doctor immediately if the patient feels unwell following excessive intake.

Overdose Management

Overdose management involves symptomatic and supportive treatment, as no specific antidote for Methionine overdose is documented in the available regulatory prescribing information. Continuous monitoring of plasma methionine levels is required to ensure concentrations are kept below 1,000 mu mol/L. A specific population note identifies patients with Cystathionine beta-synthase (CBS) deficiency as having a heightened risk for hypermethioninemia and resulting cerebral oedema.

Advertisements

Therapeutic Uses of Метионин

What Methionine Treats: Main Uses and Benefits

Methionine is commonly used in distinct clinical settings, primarily offering essential supportive relief across significant symptomatic domains that may appear suddenly or intensify over time. The substance is commonly used in situations involving acute systemic burden, where it may assist with managing symptoms related to organ-specific functional stress, such as during acetaminophen (Tylenol) poisoning. It is also relevant for treating liver disorders and managing symptoms related to inflammatory or irritative states of the skin. The overall benefit plays a role in managing symptoms that create noticeable physiological strain and contributes to a more stable experience.

Emergency Support and Liver Maintenance

Methionine is applied across several key areas: for emergency support against acute toxicity, for long-term support of impaired hepatic function like fatty liver disease (steatosis), and for easing local discomfort and irritation symptoms such as severe diaper rash and strong urine odor. It provides a foundational therapeutic benefit that assists in easing the ongoing symptom burden of conditions marked by increased physiological stress.


Quick Fact: Supportive Management for Local Symptoms
Is relevant for easing symptoms related to local irritation and hygiene concerns arising from urinary contact, which supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

The eligibility profile for Methionine-containing medicinal products is defined by strict regulatory criteria, classifying patient populations into allowed, restricted, or contraindicated groups.

Eligibility scope

Populations for whom use is allowed (as stated in label):

  • Adults and Adolescents (14-17 years), typically as a component of parenteral nutritional support.
  • Children and Adolescents (2 to 13 years), permitted only with individualized dosage adjustment.

Populations for whom use is contraindicated:

  • Newborns, Infants, and Toddlers less than 2 years of age [SmPC].
  • Patients with Severe Hepatic Insufficiency or Severe Renal Insufficiency (unless on dialysis) [SmPC].
  • Patients with known Serious Hypersensitivity or Disturbances of amino acid metabolism [SmPC].
  • Individuals in acute decompensated clinical states, including Metabolic Acidosis, Shock, or Fluid Overload [SmPC].

Pregnancy and lactation eligibility status:

  • Data Insufficient/Not Established in official labeling; use requires a physician's risk-benefit assessment.

Eligibility classifications (high-level)

Eligibility severity classification:

  • Contraindicated for severe organ failure, certain metabolic disorders, and age below two years.
  • Use with Caution/Requires Adjustment for patients with non-severe hepatic or renal impairment and those with cardiac insufficiency [SmPC].

Resulting eligibility structure Official documents define non-eligibility through absolute contraindications for specific organ and metabolic failures, prohibiting use in those unstable conditions. For eligible populations, particularly those with existing hepatic or renal insufficiency, regulatory guidance requires individualized dose adjustment and careful administration, ensuring use remains within defined safety limits.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns and restrictions for Methionine, derived strictly from governmental regulatory sources, focusing on combination constraints and pharmacodynamic risks.

Official Interaction Statements

The regulatory profile highlights constraints related to specific patient conditions and co-administered medicinal products:

  • Levodopa: Methionine may reduce the therapeutic effects of the dopaminergic agent Levodopa due to pharmacodynamic antagonism.
  • Administration Timing: In the context of acute management, Methionine administration is not effective if given following the prior administration of Activated Charcoal, imposing a strict procedural sequence.

Interaction-Related Restrictions and Contraindications

Specific metabolic and health conditions are formally listed as contraindications due to the risk of exacerbating the underlying state:

Condition / Substance Interaction Classification Official Restriction
Acidosis Pharmacodynamic Risk Contraindicated (risk of aggravation)
Severe Liver Disease Pharmacodynamic Risk Contraindicated (risk of encephalopathy)
MTHFR Deficiency Metabolic Risk Contraindicated (risk of homocysteine accumulation)

Use is also cautioned in patients with pre-existing renal insufficiency or atherosclerosis due to the metabolic risks involved. The interaction map is defined by these constraints, establishing limits on co-administration based on the patient's physiological state.

Advertisements

Mechanism of Action

Driving the Core Cellular Methylation Cycle

The primary mechanism of Methionine involves its role as a precursor that enters the Methionine Cycle, where it is activated by the enzyme Methionine Adenosyltransferase (MAT) to form S-adenosylmethionine (SAMe). This SAMe is the universal methyl-group donor required by cellular machinery, driving critical metabolic and regulatory processes such as the synthesis of phospholipids to contribute to the maintenance and structural integrity of cell membranes, particularly in the liver.

Modulation of Hepatic Antioxidant Synthesis

Methionine's subsequent metabolism is channeled into the Transsulfuration Pathway, ultimately supplying the necessary Cysteine to synthesize Glutathione (GSH). The synthesis is critical for generating the tripeptide Glutathione (GSH), which functions as the primary cellular antioxidant. This action allows GSH to scavenge toxic intermediates and neutralize reactive oxygen species (ROS), contributing directly to cellular redox balance.

Cofactor Dependency and Efficiency Limitations

The sustained biochemical flux of the Methionine Cycle is functionally constrained by the process of regenerating Methionine from its intermediate, Homocysteine. This process requires the presence of essential Vitamin B12 and Folate as cofactors for the enzyme Methionine Synthase. When these cofactors are deficient, the overall flux and the generation of active metabolites are naturally limited, restricting the pathway's operational capacity.

Advertisements

Dosage and Administration Information

How to Use Methionine: Official Administration Guidelines

Methionine administration is defined by regulatory guidelines that dictate specific routes, timing, and dosage schedules based on its intended use. The substance is officially utilized through two primary methods: the oral route (via tablets, capsules, or solutions) for supportive and acute regimens, and by intravenous (IV) infusion as an essential amino acid component in parenteral nutrition (TPN) solutions.

Oral Regimens and Timing

For standard oral use, administration timing is structured around food intake; doses are directed to be taken with, or immediately following, meals. Supportive oral regimens typically involve doses between 200 mg and 500 mg administered three to four times per day. The contents of oral capsules may be mixed into liquids such as water, juice, or formula to aid ingestion.

Acute and IV Protocols

A separate, time-critical oral regimen is established for acute care, requiring a dose of 2.5 grams given every four hours for a total of four doses, a course that must be initiated within ten hours of the acute event.

Intravenous administration for TPN requires adherence to strict procedural conditions. IV solutions must be prepared using aseptic technique and administered with an in-line filter (e.g., 1.2 micron). Furthermore, guidance specifies that IV administration to neonates and children must include measures to protect the solution from light exposure.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Methionine (Метионин)


Evidence for Use in Acute Acetaminophen Poisoning

Methionine was evaluated in studies focusing on acute toxicity, specifically cases involving acetaminophen poisoning. Studies conducted during these acute situations include emergency support protocols and clinical case reports. These trials and analyses monitored outcomes related to monitoring physiological strain or stress, specifically focusing on hepatic function biomarkers and measures of overall acute systemic burden.

Findings indicate specific patterns observed when Methionine was observed in established, combination treatment protocols for managing acute episodes. This evidence contributes to the broader evidence landscape of how specific interventions are applied during critical phases.

Long-term outcomes are not well characterized, particularly the status of patients following the initial acute management phase. Research is still emerging regarding data regarding its application outside of established, combined treatment methods and the data related to full, sustained recovery.


Evidence for Liver Disorders and Supportive Care

Methionine was evaluated in studies focusing on liver disorders, such as fatty liver disease, through long-term supportive management trials and clinical trials. Research explored how Methionine was associated with metrics related to impaired hepatic function, including specific hepatic biomarkers and general assessments of condition stability. These studies included populations with established functional issues of the liver.

Research highlights changes measured in hepatic function biomarkers over extended observation periods. Studies monitored Methionine in research contexts involving fluctuating or unstable symptoms and described the assessment of symptom burden outcomes related to physiological strain or stress.

Evidence quality varies across studies, and certainty remains low regarding long-term outcomes. There is limited information for long-term outcomes describing detailed changes in disease progression, such as in steatosis. Furthermore, findings were mixed, and evidence quality varies across studies when Methionine was studied for different types and severities of liver disorders.


Evidence for Localized Symptoms and Irritation

Methionine was studied for outcomes linked to inflammatory or irritative states, such as severe diaper rash and strong urine odor. This research examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort, used in research exploring how symptoms change over time. The studies utilized supportive relief trial designs and clinical use analyses.

Research describes patterns observed in some studies during the assessment of localized discomfort over short-term study periods. Studies reported how symptoms evolved and contributed to understanding symptom patterns associated with outcomes linked to inflammatory or irritative states. Evidence highlights what has been observed so far in terms of patterns related to management for these conditions.

The research is focused on local endpoints, and comparative evidence is lacking. Data for certain groups remain insufficient regarding the recurrence of symptoms. Results apply only to the populations studied and may be influenced by concurrent care practices.


Long-Term Studies and Follow-up Duration

Research exploring short-term symptom changes and studies conducted during periods of increased symptom activity are characterized by mixed follow-up durations. For acute issues, observation periods are typically short, restricted to the emergency phase. For chronic liver conditions, studies were observed in longer time intervals.

There is limited information for long-term outcomes describing the durability of patterns observed in the studies over many years. Research highlights what is known for defined time intervals, but there is limited information for long-term outcomes extending past the typical study duration.


Evidence in Specific Populations

Studies monitored Methionine was observed in various populations, including patients requiring comprehensive nutrition in clinical settings (IV solutions) and individuals with different severities of hepatic dysfunction. Furthermore, localized symptom management research was observed in studies relevant to children (e.g., severe diaper rash).

Research findings describe group patterns, but data for certain groups remain insufficient (such as older adults or pregnant populations). Subgroup findings are uncertain across populations with coexisting medical conditions. Results apply only to the populations studied. Research does not determine whether an individual will respond similarly.


What is Still Uncertain About Methionine Research

Evidence quality varies across studies, and certainty remains low in certain areas. Long-term effects are not fully established for chronic conditions, primarily due to limited information for long-term outcomes and follow-up durations. Comparative evidence is lacking regarding the patterns observed in the studies against other available methods for certain indications. Finally, sample sizes were modest in some trials, and subgroup findings are uncertain for certain groups or very specific outcomes.

Key Studies & References Methionine: The MTHFR Gene and You (MedlinePlus Overview)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Метионин (FAQ)

Q: Does Метионин need to be taken at a specific time of day?

Official administration guidelines specify that oral doses of Methionine should be taken with, or immediately following, meals. The regulatory documents do not generally specify restrictions or requirements related to the time of day, such as whether it should be taken in the morning or at night.

Q: Is it generally acceptable to take Метионин with my regular multivitamin?

Methionine's metabolism in the body depends on essential cofactors, particularly Vitamin B12 and Folate (B vitamins), to function correctly. While official documents do not provide a blanket statement on all multivitamin combinations, the role of these B vitamins is documented. Reviewing the use of Methionine with any co-administered products for potential interactions is generally indicated.

Q: Can Метионин be taken at the same time as prescription antibiotics?

The official product information lists specific drug interactions, such as with Levodopa and Activated Charcoal. A general interaction constraint covering all prescription antibiotics as a class is not specifically documented in the main regulatory materials.

Q: Is Метионин the same thing as SAMe (S-adenosylmethionine)?

No, they are not the same substance. Methionine is the essential amino acid that serves as a precursor molecule. The body chemically activates Methionine to form S-adenosylmethionine (SAMe), which is the active compound that drives the crucial methylation cycle.

Q: Does Метионин help with detox or cleanse the body?

Official information describes Methionine as supporting overall cellular health and detoxification. This function is linked to its metabolism, which results in the formation of Glutathione, a powerful cellular antioxidant that contributes to the management of toxic substances.

Q: If I miss a dose of Метионин, what generally happens?

For some Methionine-containing treatments, regulatory guidance indicates that if a dose is missed, treatment is generally continued as normal at the next scheduled administration time.

Q: Can certain foods interact with Метионин?

Official guidelines direct that oral doses be taken with, or immediately following, meals. While the regulatory documents do not list specific food-drug interactions, regulatory documents note that the use of the medicine with food should be discussed with a healthcare professional.

Q: Is there a known interaction between Метионин and over-the-counter pain relievers?

The official drug labels list specific drug interactions. A general interaction constraint covering all over-the-counter pain relievers as a class is not specifically documented in the main regulatory materials.

Q: Is Метионин appropriate for use by elderly people?

Official eligibility classifications do not list advanced age as a specific contraindication for Methionine. Use for all adult populations is subject to the general contraindications and caution criteria listed in the label, especially concerning pre-existing conditions.

Q: Are there different forms or salts of Метионин, and do they matter?

Yes, Methionine is available in different forms, including the biologically active L-Methionine and the synthetic mixture DL-Methionine. Regulatory documentation also defines its existence in various salt forms, such as Choline Methionine Tartrate and Zinc Methionine Sulfate, which are commonly used in nutritional combination products.

Q: Why is high intake of Метионин sometimes discussed in health communities?

The discussion is likely related to the publicly documented safety profile. Official information notes that adverse reactions and serious safety constraints—such as elevated blood homocysteine and altered serum pH (acidosis)—are generally dose-dependent and concentrate at high intake levels.

Q: Is it common for people to feel fatigued when first starting Метионин?

Fatigue is not listed as a documented common adverse reaction for Methionine in the main regulatory safety information. The officially documented nervous system adverse reactions include Headache, Agitation, and Confusion, which are generally associated with high doses.

Q: Can Метионин make certain urine tests show unusual results?

Scientific literature indicates that Methionine can lower the pH of the urine (acidification). This chemical effect on urine pH is a factor that may be relevant to the interpretation of certain laboratory tests.

Q: Does Метионин interact with common herbal supplements like St. John's Wort?

The official drug labels list specific, constrained drug interactions. A general interaction constraint covering common herbal supplements like St. John's Wort is not specifically documented in the main regulatory materials.

Q: Can Метионин affect mood or sleep patterns?

Official safety information documents effects on the nervous system, including potential adverse reactions such as Agitation and Confusion. These effects are generally associated with high doses and relate to an individual's mental state.

Q: Is it possible to take too much Метионин from food and supplements combined?

Yes, official safety information indicates that adverse reactions for Methionine are generally dose-dependent and associated with high intake levels. This safety framework emphasizes that the primary risks are tied to pre-existing conditions and the overall dose-dependent toxicity.

Q: Can people who are vegetarian or vegan take Метионин?

Methionine is classified as an essential amino acid, meaning the body requires a dietary source. The drug substance itself is typically synthesized in a laboratory. The suitability of the final product for vegetarian or vegan diets depends on the specific ingredients in the final tablet or capsule formulation, such as the casing materials.

Q: Is Метионин ever given as an injection instead of an oral pill?

Yes. While oral forms (pills, tablets) are common, official administration guidelines also utilize Methionine by intravenous (IV) infusion. In this form, it is administered as an essential amino acid component in parenteral nutrition solutions, which is done in a clinical setting.

Q: Is the general research on Метионин recent or historical?

Official overviews describe the evidence as spanning both historical studies, such as those related to acute toxicity management, and still emerging research. There is ongoing data collection regarding its general application and long-term outcomes.

Q: Why is it sometimes recommended to take Метионин with B vitamins?

The requirement for cofactors provides the biochemical rationale. The sustained process of the Methionine Cycle is functionally constrained by the presence of essential cofactors, specifically Vitamin B12 and Folate, which are necessary to regenerate Methionine from an intermediate in the body.

Q: Does Метионин interfere with birth control pills?

The official drug labels list specific drug interactions. An interaction constraint covering birth control pills is not specifically documented in the main regulatory materials.

Advertisements

How should Метионин be stored and disposed of?

Storage and Disposal of Methionine-Containing Products

The storage and disposal requirements for Methionine depend on the specific formulation, such as oral products or intravenous solutions.

Storage Requirements

Many parenteral solutions should be stored at room temperature, typically 25 C (77 F), but certain prepared admixtures must be stored under refrigeration.

Storage of specific formulations may require protection from light after the original external packaging is removed. Products must be stored out of the sight and reach of children.

Stability and Handling

Regulatory documents define strict time limits for use after opening: for instance, a Pharmacy Bulk Package must be used, and the container discarded, within 4 hours of the initial puncture. Prepared admixtures are generally stable for 24 hours when refrigerated.

Disposal

Unused or expired product should generally be disposed of in household trash after being mixed with an undesirable substance (e.g., dirt or litter) and placed in a sealed container. Do not flush the medicine down the toilet or pour it down a sink unless the official label explicitly directs this disposal method. Any unused portion of single-use containers in a clinical setting must be properly discarded as pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Метионин found in:

A-Z Index: